Sutro Biopharma (STRO) Total Non-Current Liabilities (2016 - 2025)

Sutro Biopharma has disclosed Total Non-Current Liabilities across 10 years of filings, most recently posting $304.6 million for Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $304.6 million, down 10.65% year-over-year; the trailing twelve-month figure through Dec 2025 was $304.6 million (down 10.65% YoY), and the FY2025 annual result was $304.6 million, down 10.65% from the prior year.
• Total Non-Current Liabilities came in at $304.6 million for Q4 2025 at Sutro Biopharma, up from $295.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $345.5 million in Q1 2025 to a low of $50.6 million in Q1 2021.
• The 5-year median for Total Non-Current Liabilities is $292.8 million (2025), against an average of $222.0 million.
• Across the five-year window, Total Non-Current Liabilities declined 29.44% in 2021 and soared 242.94% in 2022, its largest moves.
• Sutro Biopharma's Total Non-Current Liabilities stood at $88.7 million in 2021, then jumped by 113.96% to $189.8 million in 2022, then surged by 68.3% to $319.4 million in 2023, then increased by 6.74% to $340.9 million in 2024, then decreased by 10.65% to $304.6 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $304.6 million (Q4 2025), $295.2 million (Q3 2025), and $292.8 million (Q2 2025), per Business Quant data.